1. Release of Patients who have been Administered a Radiopharmaceutical (Notice No. 1108–2 from the Division for Guidance on Medical Care, Health Policy Bureau dated November 8, 2010, Notice from the Head of the Division for Guidance on Medical Care, Health Policy Bureau, Ministry of Health, Labor, and Welfare).
2. Release of Patients who have been Administered a Radiopharmaceutical (Notice No. 70 from the Safety Division, Pharmaceutical and Medical Safety Bureau dated June 30, 1998, Notice from the Head of the Safety Division, Pharmaceutical and Medical Safety Bureau.
3. Swärd C, Bernhardt P, Ahlman H, Wängberg B, Forssell-Aronsson E, Larsson M, et al. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: The value of measuring absorbed dose to the kidney. World J Surg. 2010;34(6):1368–72.
4. Kwekkeboom D, de Herder W, Kam B, van Eijck C, van Essen M, Kooij P, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.
5. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I–II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.